Laverock Therapeutics develops a programmable gene-control platform to create disease-responsive advanced therapies. The platform has been demonstrated across multiple therapeutic applications and cell types, including programmed T‑cell and macrophage therapies for solid tumors and hypoimmunogenic pancreatic islet cell programs targeting Type 1 diabetes. The company plans to scale its platform within T‑cell therapies using single-cell technologies, AI approaches, and patient-derived models to improve efficacy and safety in solid tumors. It also aims to expand its macrophage-based programs into non-oncology indications through consortium-driven development. Laverock is advancing toward clinical development of its lead programme and is using recent non-dilutive grant funding to strengthen both platform capability and pipeline expansion. Recent non-dilutive awards include over £2.2 million in the latest grants and a prior £1.8 million from UK Research and Innovation programmes.

Total raised

$46M

Funding rounds

3

Latest round

Grant

Latest activity

Jun 2026